FDA.reportPublic FDA data

Humira

Product NDC
0074-0817
11-digit product format
000740817
Labeler code
0074
Product ID
0074-0817_8bf84b15-6763-41cf-bfa4-bcee9ad4ef9a
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
Adalimumab
Dosage form
KIT
Labeler
AbbVie Inc.
Application
BLA125057
Marketing category
BLA
Marketing start
2017-04-28
NDC exclude flag
No
Listing certified through
2027-12-31
Current FDA listing
Yes

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
HumiraADALIMUMABAbbVie Inc.608d4f0d-b19f-46d3-749a-7159aa5f933d2025-12-23Boxed warning, Warnings, Adverse reactionsExact identifier

Boxed warning cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

boxed warning

WARNING: SERIOUS INFECTIONS AND MALIGNANCY SERIOUS INFECTIONS Patients treated with HUMIRA are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions ( 5.1 )] . Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue HUMIRA if a patient develops a serious infection or sepsis. Reported infections include: ● Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before HUMIRA use and during therapy. Initiate treatment for latent TB prior to HUMIRA u se. ● Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who d evelop severe systemic illness. ● Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria. Carefully consider the risks and benefits of treatment with HUMIRA prior to initiating therapy in patients with chronic or recurrent infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with HUMIRA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy [see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.1 )] . MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including HUMIRA [see Warnings and Precautions ( 5.2 )] . Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including HUMIRA. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young a...

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Serious infections: Do not start HUMIRA during an active infection. If an infection develops, monitor carefully, and stop HUMIRA if infection becomes serious. ( 5.1 ) Invasive fungal infections: For patients who develop a systemic illness on HUMIRA, consider empiric antifungal therapy for those who reside or travel to regions where mycoses are endemic. ( 5.1 ) Malignancies: Incidence of malignancies was greater in HUMIRA-treated patients than in controls ( 5.2 ) Anaphylaxis or serious hypersensitivity reactions may occur ( 5.3 ) Hepatitis B virus reactivation: Monitor HBV carriers during and several months after therapy. If reactivation occurs, stop HUMIRA and begin anti-viral therapy. ( 5.4 ) Demyelinating disease: Exacerbation or new onset, may occur. ( 5.5 ) Cytopenias, pancytopenia: Advise patients to seek immediate medical attention if symptoms develop, and consider stopping HUMIRA. ( 5.6 ) Heart failure: Worsening or new onset, may occur. ( 5.8 ) Autoimmunity : Stop HUMIRA if lupus-like syndrome or autoimmune hepatitis develops. ( 5.9 ) 5.1 Serious Infections Patients treated with HUMIRA are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death. Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers. Patients have frequently presented with disseminated rather than localized disease. The concomitant use of a TNF blocker and abatacept or anakinra was associated with a higher risk of serious infections in patients with rheumatoid arthritis (RA); therefore, the concomitant use of HUMIRA and these biologic products is not recommended in the treatment of patients with RA [see Warnings and Precautions ( 5.7 , 5.11 ) and Drug Interactions ( 7.2 )] . Treatment with HUMIRA should not be initiated in patients with an active infection, including localized infections. Patients 65 years of age and older, patients with co-morbid conditions and/or patients taking concomitant immunosuppressants (such as corticosteroids or methotrexate), may be at greater risk of infection. Consider the risks and benefits of...

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

adverse reactions

6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Serious Infections [see Warnings and Precautions ( 5.1 ) ] Malignancies [see Warnings and Precautions ( 5.2 ) ] Hypersensitivity Reactions [see Warnings and Precautions ( 5.3 ) ] Hepatitis B Virus Reactivation [see Warnings and Precautions ( 5.4 ) ] Neurologic Reactions [see Warnings and Precautions ( 5.5 ) ] Hematological Reactions [see Warnings and Precautions ( 5.6 ) ] Heart Failure [see Warnings and Precautions ( 5.8 ) ] Autoimmunity [see Warnings and Precautions ( 5.9 ) ] Most common adverse reactions (>10%) are: infections (e.g. upper respiratory, sinusitis), injection site reactions, headache and rash. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact AbbVie Inc. at 1-800-633-9110 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The most common adverse reaction with HUMIRA was injection site reactions. In placebo-controlled trials, 20% of subjects treated with HUMIRA developed injection site reactions (erythema and/or itching, hemorrhage, pain or swelling), compared to 14% of subjects receiving placebo. Most injection site reactions were described as mild and generally did not necessitate drug discontinuation. The proportion of subjects who discontinued treatment due to adverse reactions during the double-blind, placebo-controlled portion of studies in subjects with RA (i.e., Studies RA-I, RA-II, RA-III and RA-IV) was 7% for subjects taking HUMIRA and 4% for placebo-treated subjects. The most common adverse reactions leading to discontinuation of HUMIRA in these RA studies were clinical flare reaction (0.7%), rash (0.3%) and pneumonia (0.3%). Infections In the controlled portions of the 39 global HUMIRA clinical trials in adult subjects with RA, PsA, AS, CD, UC, Ps, HS and UV, the rate of serious infections was 4.3 per 100 patient-years in 7973 HUMIRA-treated subjects versus a rate of 2.9 per 100 patient-years in 4848 control-treated subjects. Serious infections observed included pneumonia, septic arthritis, prosthetic and post-surgical inf...

adverse reactions table

Table 1. Adverse Reactions Reported by ≥5% of Subjects Treated with HUMIRA During Placebo-Controlled Period of Pooled RA Studies (Studies RA-I, RA-II, RA-III, and RA-IV) HUMIRA 40 mg subcutaneous Every Other Week Placebo (N=705)(N=690)Adverse Reaction (Preferred Term) Respiratory Upper respiratory infection17%13% Sinusitis11%9% Flu syndrome7%6%Gastrointestinal Nausea9%8% Abdominal pain7%4%Laboratory Tests* Laboratory test abnormal8%7% Hypercholesterolemia6%4% Hyperlipidemia7%5% Hematuria5%4% Alkaline phosphatase increased5%3%Other Headache12%8% Rash12%6% Accidental injury10%8% Injection site reaction **8%1% Back pain6%4% Urinary tract infection8%5% Hypertension5%3%* Laboratory test abnormalities were reported as adverse reactions in European trials ** Does not include injection site erythema, itching, hemorrhage, pain or swelling

Additional Listing Data#

Finished product
Yes
Brand name base
Humira
Listing expiration
2027-12-31

Harmonized Identifiers#

Field, Values table
FieldValues
Rxcui727703, 727705, 763564, 763565, 797544, 825169, 825170, 1594352, 1594357, 1594358, 1655726, 1655728, 1656703, 1726844, 1726846, 1801277, 1801278, 1855523, 1855524, 1855526

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
58819a18-327d-463b-9e5e-26cc1dd9870dProduct name120230313
c1c5a070-0e2e-43dd-af9c-a21585200342Product name120230104
2a463079-cd68-4798-a3d6-55c4c8578d57Product name120220728
652f8f6b-479d-477c-848a-374d5b0145b7Product name220151203

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0074-0817-02Humira2 in 1 CARTONKIT22154
0074-0817-02Humira1 in 1 KITKIT12154

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0074-0817-02EA - Each0074-08179858fc46-19f5-46db-9141-57e0fdec19a612018-05-09

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIIDailyMed labelSPL versionUploaded
ADALIMUMABACTIVE INGREDIENTFYS6T7F842HUMIRA (ADALIMUMAB) KIT HUMIRA (ADALIMUMAB) INJECTION, SOLUTION [ABBVIE INC.]1805
ISOPROPYL ALCOHOLACTIVE INGREDIENTND2M416302HUMIRA (ADALIMUMAB) KIT HUMIRA (ADALIMUMAB) INJECTION, SOLUTION [ABBVIE INC.]1805
ADALIMUMABACTIVE MOIETYFYS6T7F842HUMIRA (ADALIMUMAB) KIT HUMIRA (ADALIMUMAB) INJECTION, SOLUTION [ABBVIE INC.]1805
ISOPROPYL ALCOHOLACTIVE MOIETYND2M416302HUMIRA (ADALIMUMAB) KIT HUMIRA (ADALIMUMAB) INJECTION, SOLUTION [ABBVIE INC.]1805
CITRIC ACID MONOHYDRATEINACTIVE INGREDIENT2968PHW8QPHUMIRA (ADALIMUMAB) KIT HUMIRA (ADALIMUMAB) INJECTION, SOLUTION [ABBVIE INC.]1805
MANNITOLINACTIVE INGREDIENT3OWL53L36AHUMIRA (ADALIMUMAB) KIT HUMIRA (ADALIMUMAB) INJECTION, SOLUTION [ABBVIE INC.]1805
POLYSORBATE 80INACTIVE INGREDIENT6OZP39ZG8HHUMIRA (ADALIMUMAB) KIT HUMIRA (ADALIMUMAB) INJECTION, SOLUTION [ABBVIE INC.]1805
SODIUM CHLORIDEINACTIVE INGREDIENT451W47IQ8XHUMIRA (ADALIMUMAB) KIT HUMIRA (ADALIMUMAB) INJECTION, SOLUTION [ABBVIE INC.]1805
SODIUM CITRATE, UNSPECIFIED FORMINACTIVE INGREDIENT1Q73Q2JULRHUMIRA (ADALIMUMAB) KIT HUMIRA (ADALIMUMAB) INJECTION, SOLUTION [ABBVIE INC.]1805
SODIUM HYDROXIDEINACTIVE INGREDIENT55X04QC32IHUMIRA (ADALIMUMAB) KIT HUMIRA (ADALIMUMAB) INJECTION, SOLUTION [ABBVIE INC.]1805
SODIUM PHOSPHATE, DIBASIC, DIHYDRATEINACTIVE INGREDIENT94255I6E2THUMIRA (ADALIMUMAB) KIT HUMIRA (ADALIMUMAB) INJECTION, SOLUTION [ABBVIE INC.]1805
SODIUM PHOSPHATE, MONOBASIC, DIHYDRATEINACTIVE INGREDIENT5QWK665956HUMIRA (ADALIMUMAB) KIT HUMIRA (ADALIMUMAB) INJECTION, SOLUTION [ABBVIE INC.]1805
WATERINACTIVE INGREDIENT059QF0KO0RHUMIRA (ADALIMUMAB) KIT HUMIRA (ADALIMUMAB) INJECTION, SOLUTION [ABBVIE INC.]1805

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
0074-0817HUMIRA (ADALIMUMAB) KIT HUMIRA (ADALIMUMAB) INJECTION, SOLUTION [ABBVIE INC.]2148Current NDC, Legacy NDC, 2 package rows20240210_608d4f0d-b19f-46d3-749a-7159aa5f933d.zip

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
125057Humiraadalimumab351(a)Rx2026-06-01

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYDailyMedSPL version
1855527{1 (0.4 ML adalimumab 100 MG/ML Prefilled Syringe [Humira]) / 1 (0.8 ML adalimumab 100 MG/ML Prefilled Syringe [Humira]) } Pack [Humira Pediatric Crohn's Disease Starter Package (2 count)]BPCK608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1921468{2 (0.4 ML adalimumab 100 MG/ML Auto-Injector [Humira]) / 1 (0.8 ML adalimumab 100 MG/ML Auto-Injector [Humira]) } Pack [Humira Pen 80 MG/0.8 ML and 40 MG/0.4 ML - Psoriasis/Uveitis Starter Package]BPCK608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1921245{3 (0.8 ML adalimumab 100 MG/ML Auto-Injector [Humira]) } Pack [Humira Pen 80 MG/0.8 ML - Starter Package for Crohn's Disease, Ulcerative Colitis or Hidradenitis Suppurativa]BPCK608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1873087{3 (0.8 ML adalimumab 100 MG/ML Prefilled Syringe [Humira]) } Pack [Humira Prefilled Syringe 80 MG/0.8 ML Starter Pack - Pediatric Crohn's Disease]BPCK608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1594358{3 (0.8 ML adalimumab 50 MG/ML Prefilled Syringe [Humira]) } Pack [Humira Pediatric Crohn's Disease Starter Package (3 count)]BPCK608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1872986{4 (0.4 ML adalimumab 100 MG/ML Auto-Injector [Humira]) } Pack [Humira Pen 40 MG/0.4 ML Starter Pack - Psoriasis]BPCK608d4f0d-b19f-46d3-749a-7159aa5f933d2154
2531134{4 (0.8 ML adalimumab 100 MG/ML Auto-Injector [Humira]) } Pack [Humira Pen 80 MG/0.8 ML - Starter Package for Pediatric Ulcerative Colitis]BPCK608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1801278{4 (0.8 ML adalimumab 50 MG/ML Auto-Injector [Humira]) } Pack [Humira Pen - Psoriasis Starter Pack]BPCK608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1872984{6 (0.4 ML adalimumab 100 MG/ML Auto-Injector [Humira]) } Pack [Humira Pen 40 MG/0.4 ML Starter Pack - Crohn's Disease]BPCK608d4f0d-b19f-46d3-749a-7159aa5f933d2154
825170{6 (0.8 ML adalimumab 50 MG/ML Auto-Injector [Humira]) } Pack [Humira Pen - Crohn's Disease Starter Pack]BPCK608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1594352{6 (0.8 ML adalimumab 50 MG/ML Prefilled Syringe [Humira]) } Pack [Humira Pediatric Crohn's Disease Starter Package (6 count)]BPCK608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1855526{1 (0.4 ML adalimumab 100 MG/ML Prefilled Syringe) / 1 (0.8 ML adalimumab 100 MG/ML Prefilled Syringe) } PackGPCK608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1921467{2 (0.4 ML adalimumab 100 MG/ML Auto-Injector) / 1 (0.8 ML adalimumab 100 MG/ML Auto-Injector) } PackGPCK608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1921244{3 (0.8 ML adalimumab 100 MG/ML Auto-Injector) } PackGPCK608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1873086{3 (0.8 ML adalimumab 100 MG/ML Prefilled Syringe) } PackGPCK608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1594357{3 (0.8 ML adalimumab 50 MG/ML Prefilled Syringe) } PackGPCK608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1872985{4 (0.4 ML adalimumab 100 MG/ML Auto-Injector) } PackGPCK608d4f0d-b19f-46d3-749a-7159aa5f933d2154
2531133{4 (0.8 ML adalimumab 100 MG/ML Auto-Injector) } PackGPCK608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1801277{4 (0.8 ML adalimumab 50 MG/ML Auto-Injector) } PackGPCK608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1872983{6 (0.4 ML adalimumab 100 MG/ML Auto-Injector) } PackGPCK608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1656703{6 (0.8 ML adalimumab 50 MG/ML Auto-Injector) } PackGPCK608d4f0d-b19f-46d3-749a-7159aa5f933d2154
825169{6 (0.8 ML adalimumab 50 MG/ML Prefilled Syringe) } PackGPCK608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1921009adalimumab 10 MG in 0.1 ML Prefilled SyringePSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1921016adalimumab 20 MG in 0.2 ML Prefilled SyringePSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
763564adalimumab 20 MG in 0.4 ML Prefilled SyringePSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1872979adalimumab 40 MG in 0.4 ML Auto-InjectorPSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1726844adalimumab 40 MG in 0.4 ML Prefilled SyringePSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1655726adalimumab 40 MG in 0.8 ML Auto-InjectorPSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
727703adalimumab 40 MG in 0.8 ML Prefilled SyringePSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1921238adalimumab 80 MG in 0.8 mL Auto-InjectorPSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1855523adalimumab 80 MG in 0.8 ML Prefilled SyringePSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1594357adalimumab pediatric starter pack 40 MG/0.8 ML Prefilled Syringe (3 count)PSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
825169adalimumab pediatric starter pack 40 MG/0.8 ML Prefilled Syringe (6 count)PSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1855526adalimumab pediatric starter pack 80 MG/0.8 ML and 40 MG/0.4 ML Prefilled Syringe (2 count)PSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1873086adalimumab pediatric starter pack 80 MG/0.8 ML Prefilled Syringe (3 count)PSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1872985adalimumab starter pack 40 MG/0.4 ML Pen (4 count)PSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1872983adalimumab starter pack 40 MG/0.4 ML Pen (6 count)PSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1801277adalimumab starter pack 40 MG/0.8 ML Pen (4 count)PSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1656703adalimumab starter pack 40 MG/0.8 ML Pen (6 count)PSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1921467adalimumab starter pack 80 MG/0.8 mL and 40 MG/0.4 mL Auto-Injector (3 count)PSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1921244adalimumab starter pack 80 MG/0.8 mL Auto-Injector (3 count)PSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
2531133adalimumab starter pack 80 MG/0.8 ML Pen (4 count)PSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1921010Humira 10 MG in 0.1 ML Prefilled SyringePSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1921017Humira 20 MG in 0.2 ML Prefilled SyringePSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
763565Humira 20 MG in 0.4 ML Prefilled SyringePSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1872980Humira 40 MG in 0.4 ML Auto-InjectorPSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1726846Humira 40 MG in 0.4 ML Prefilled SyringePSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1655728Humira 40 MG in 0.8 ML Auto-InjectorPSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
727705Humira 40 MG in 0.8 ML Prefilled SyringePSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1921240Humira 80 MG in 0.8 mL Auto-InjectorPSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1855524Humira 80 MG in 0.8 ML Prefilled SyringePSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1855527Humira Pediatric Crohn's Disease Starter Package (2 count)PSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1594358Humira Pediatric Crohn's Disease Starter Package (3 count)PSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1594352Humira Pediatric Crohn's Disease Starter Package (6 count)PSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1872984Humira Pen 40 MG/0.4 ML Starter Pack - Crohn's Disease, Ulcerative Colitis or Hidradenitis Suppurativa (6 count)PSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1872986Humira Pen 40 MG/0.4 ML Starter Pack - Psoriasis/Uveitis (4 count)PSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
825170Humira Pen 40 MG/0.8 ML - Crohn's Disease/Ulcerative Colitis Starter PackPSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1921245Humira Pen 80 MG/0.8 ML - Starter Package for Crohn's Disease, Ulcerative Colitis or Hidradenitis Suppurativa (3 count)PSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
2531134Humira Pen 80 MG/0.8 ML - Starter Package for Pediatric Ulcerative Colitis (4 count)PSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1921468Humira Pen 80 MG/0.8 ML and 40 MG/0.4 ML - Psoriasis/Uveitis Starter Package (3 count)PSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1873087Humira Prefilled Syringe 80 MG/0.8 ML Starter Pack - Pediatric Crohn's Disease (3 count)PSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
1801278Humira Psoriasis/Uveitis Starter Pack 40 MG/0.8 ML Pen (4 count)PSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
797544isopropyl alcohol 70 % Medicated PadPSN608d4f0d-b19f-46d3-749a-7159aa5f933d2154
19210100.1 ML adalimumab 100 MG/ML Prefilled Syringe [Humira]SBD608d4f0d-b19f-46d3-749a-7159aa5f933d2154
19210170.2 ML adalimumab 100 MG/ML Prefilled Syringe [Humira]SBD608d4f0d-b19f-46d3-749a-7159aa5f933d2154
18729800.4 ML adalimumab 100 MG/ML Auto-Injector [Humira]SBD608d4f0d-b19f-46d3-749a-7159aa5f933d2154
17268460.4 ML adalimumab 100 MG/ML Prefilled Syringe [Humira]SBD608d4f0d-b19f-46d3-749a-7159aa5f933d2154
7635650.4 ML adalimumab 50 MG/ML Prefilled Syringe [Humira]SBD608d4f0d-b19f-46d3-749a-7159aa5f933d2154
19212400.8 ML adalimumab 100 MG/ML Auto-Injector [Humira]SBD608d4f0d-b19f-46d3-749a-7159aa5f933d2154
18555240.8 ML adalimumab 100 MG/ML Prefilled Syringe [Humira]SBD608d4f0d-b19f-46d3-749a-7159aa5f933d2154
16557280.8 ML adalimumab 50 MG/ML Auto-Injector [Humira]SBD608d4f0d-b19f-46d3-749a-7159aa5f933d2154
7277050.8 ML adalimumab 50 MG/ML Prefilled Syringe [Humira]SBD608d4f0d-b19f-46d3-749a-7159aa5f933d2154
19210090.1 ML adalimumab 100 MG/ML Prefilled SyringeSCD608d4f0d-b19f-46d3-749a-7159aa5f933d2154
19210160.2 ML adalimumab 100 MG/ML Prefilled SyringeSCD608d4f0d-b19f-46d3-749a-7159aa5f933d2154
18729790.4 ML adalimumab 100 MG/ML Auto-InjectorSCD608d4f0d-b19f-46d3-749a-7159aa5f933d2154
17268440.4 ML adalimumab 100 MG/ML Prefilled SyringeSCD608d4f0d-b19f-46d3-749a-7159aa5f933d2154
7635640.4 ML adalimumab 50 MG/ML Prefilled SyringeSCD608d4f0d-b19f-46d3-749a-7159aa5f933d2154
19212380.8 ML adalimumab 100 MG/ML Auto-InjectorSCD608d4f0d-b19f-46d3-749a-7159aa5f933d2154
18555230.8 ML adalimumab 100 MG/ML Prefilled SyringeSCD608d4f0d-b19f-46d3-749a-7159aa5f933d2154
16557260.8 ML adalimumab 50 MG/ML Auto-InjectorSCD608d4f0d-b19f-46d3-749a-7159aa5f933d2154

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionUnitsMarketing startMarketing endSampleExclude flagStatus
0074-0817-02000740817022 KIT in 1 CARTON (0074-0817-02) / 1 KIT in 1 KIT * 1 SYRINGE in 1 TRAY / .1 mL in 1 SYRINGE * 1 mL in 1 PACKET2 kit2017-04-280000-00-00NoNoCurrent